http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2004033667-A2
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f5d1ac47a0b7cf0981654becfe992d9b |
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-1203 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5091 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 |
filingDate | 2003-10-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_547c158a1c09ea0a160e750f87b42a4d |
publicationDate | 2004-04-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | WO-2004033667-A2 |
titleOfInvention | Detection, localization and staging of tumors using labeled activated lymphocytes directed to a tumor specific epitope |
abstract | Disclosed are methods for detecting and localizing a cell-specific antigen in a mammal, such as a human subject, comprising exposing peripheral blood mononuclear cells (PBMCs) of the mammal to an immunogenic peptide epitope of the antigen, under conditions for antigen-specific activation of T lymphocytes in the PBMCs, thereby producing antigen-specific T lymphocytes that at least bind to the cell-specific antigen. Labeled antigen-specific T lymphocytes are administered to the mammal, typically without IL-2, either intraperitoneally or intravenously. The distribution of these cells in the mammal is determined by imaging, thereby detecting and localizing cell-specific antigen in the mammal. Exposing PBMCs to the immunogenic peptide typically involves a cell-free peptide preparation and interleukin-2 (IL-2), but no additional cells such as antigen presenting cells (APC) separately pulsed with antigen. The antigen-specific T lymphocytes typically are cytolytic for cells expressing the cell-specific antigen and may comprise CD4+, CD8+, and/or CD45RO+ memory T cells. |
isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10537609-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2016105536-A3 |
priorityDate | 2002-10-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 329.